Author

Tycel Phillips

Observed names: T. Phillips, Tycel J. Phillips

Institutions: City Of Hope National Medical Center, City of Hope, U-M Rogel Cancer Center

Observed institutions: City Of Hope National Medical Center, University of Michigan, City of Hope, U-M Rogel Cancer Center

ORCID: 0000-0003-2143-9672

Observed ORCID: 0000-0003-2143-9672

OpenAlex ID: A5123363840

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

2020 · Franck Morschhauser, Hervé Tilly, et al. · The Lancet Oncology · 607

Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas

2022 · Franck Morschhauser, Gilles Salles, et al. · Blood Reviews · 25

PDF

Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma

2025 · Annie Xiao, Lu Chen, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 7

P1213: Subcutaneous Epcoritamab With Gemox Induced High Response Rates in Patients With Relapsed/refractory Diffuse Large B-cell Lymphoma Ineligible for Autologous Stem Cell Transplant

2022 · B. E. Wahlin, J. Brody, et al. · HemaSphere · 5

Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial

2026 · Yasmin H. Karimi, Chan Y. Cheah, et al. · Annals of Hematology · 4

PDF

Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025

2026 · Alexey V. Danilov, Catherine C. Coombs, et al. · Cancer · 1

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017–2024)

2026 · Tycel Phillips, Ziqi Zhou, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

2025 · Swetha Thiruvengadam, Nishita Matangi, et al. · Blood · 1

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation

2026 · Tamer Othman, Dongyun Yang, et al. · Transplantation and Cellular Therapy

Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma

2026 · Alexey Danilov, Sonia Rodriguez-Rodriguez, et al. · Research Square

PDF

Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma

2026 · Carly Roleder, Xiaofan Zhao, et al. · Cancer Research Communications

Abstract 7307: Cyclin-dependent kinase 5 (CDK5) contributes to Bruton tyrosine kinase inhibitor (BTKI) resistance via IRE1α/Xbp1s axis in mantle cell lymphoma (MCL)

2026 · Sonia Rodriguez-Rodriguez, Keika Yan, et al. · Cancer Research

A Match Made in Heaven? How the Addition of Polatuzumab Vedotin to Bispecific Antibodies Has Improved Outcomes in Second-Line Diffuse Large B-Cell Lymphoma

2026 · Tycel Phillips · The Hematologist

Search for the Fountain of Youth: Can Bispecific Antibodies Resurrect Dysfunctional T Cells to Improve Outcomes in Richter Transformation?

2026 · Tycel Phillips · The Hematologist

The Coming Wave: How Bispecific Antibodies Are Pushing Into Early Lines of Therapy and What This Means for Academic and Community Practices

2026 · Tycel Phillips · The Hematologist

Front of the Line: How Does the frontMIND Study Affect Newly Diagnosed Diffuse Large B-Cell Lymphoma?

2026 · Tycel Phillips · The Hematologist

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

2025 · Swetha Thiruvengadam, Lu Chen, et al. · Blood

Bispecific Antibody Treatment for Diffuse Large B Cell Lymphoma, a Real-World Evidence (RWE) Study

2025 · Geoffrey Shouse, Swetha Thiruvengadam, et al. · Transplantation and Cellular Therapy

Does This Star ‘GLO’? Taking Aim at Second-Line Diffuse Large B-Cell Lymphoma With Glofitamab Plus Gemcitabine and Oxaliplatin

2025 · Tycel Phillips · The Hematologist

Hope for a New Standard of Care for Newly Diagnosed Diffuse Large B-Cell Lymphoma

2025 · Tycel Phillips · The Hematologist

Works count: 20

Citation count: 651

H-index: 4

I10-index: 2